Torixib Dosage/Direction for Use

TORIXIB should be administered for the shortest duration possible and the lowest effective daily dose should be used.
TORIXIB consists of 90 & 120mg tablets. TORIXIB tablet is not able to deliver all approved dose regimens of etoricoxib. Therefore, other approved dosage forms and strengths of etoricoxib should be used in such cases.
Osteoarthritis: The recommended dose is 30mg or 60mg once daily.
Rheumatoid Arthritis: The recommended dose is 60mg or 90mg once daily. The minimum effective daily dose is 60mg once daily. In some patients, 90mg once daily may provide increased therapeutic benefit.
Ankylosing Spondylitis: The recommended dose is 60mg or 90mg once daily. The minimum effective daily dose is 60mg once daily. In some patients, 90mg once daily may provide increased therapeutic benefit.
Acute Pain: In the following acute painful conditions, TORIXIB should be used only for the acute symptomatic period, limited to a maximum of 8 days treatment: Acute Gouty Arthritis: The recommended dose is 120mg once daily.
Primary Dysmenorrhea: The recommended dose is 120mg once daily.
Minor Dental Procedures: The recommended dose is 90mg once daily.
Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied. Therefore: The dose for OA should not exceed 60mg daily.
The dose for RA should not exceed 90mg daily.
The dose for ankylosing spondylitis should not exceed 90mg daily.
The dose for acute gout should not exceed 120mg daily.
The dose for acute pain and primary dysmenorrhea should not exceed 120mg daily.
The dose for minor dental procedures should not exceed 90mg daily.
Given the association between cardiovascular risk and exposure to COX-2 Inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment the patient's need for symptomatic relief and response to therapy should be re-evaluated periodically.
Elderly, Gender, Race: No dosage adjustment in TORIXIB is necessary for the elderly or based on gender or race.
Hepatic Insufficiency: In patients with mild hepatic insufficiency (Child-Pugh score 5-6), a dose of 60mg once daily should not be exceeded. In patients with moderate hepatic insufficiency (Child-Pugh score 7-9), the dose should be reduced; a dose of 60mg every other day should not be exceeded, administration of 30mg once daily can also be considered. There are no clinical or pharmacokinetic data in patients with severe hepatic insufficiency (Child-Pugh score >9).
Renal Insufficiency: In patients with advanced renal disease (creatinine clearance <30mL/min), treatment with TORIXIB is not recommended. No dosage adjustment is necessary for patients with lesser degrees of renal insufficiency (creatinine clearance ≥30mL/min).
Route of Administration(s): TORIXIB is administered orally. TORIXIB may be taken with or without food.